# A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

> **NCT00727597** · PHASE3 · COMPLETED · sponsor: **Georgetown University** · enrollment: 101 (actual)

## Conditions studied

- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** Efavirenz 600mg
- **DRUG:** Boosted Lexiva

## Key facts

- **NCT ID:** NCT00727597
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-08
- **Final completion:** 2011-07
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2013-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727597, "A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00727597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*